多发性骨髓瘤患者意外过量使用伊沙佐米。
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
机构信息
SUNY Upstate Medical University, Syracuse, NY, USA.
出版信息
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211013230. doi: 10.1177/23247096211013230.
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the management of multiple myeloma has made it easier for patients who do not have to come to the hospital for chemotherapy infusions. However, many barriers are associated with oral chemotherapy, and one of them is a misinterpretation of instruction which can have deleterious effects. In this case report, we present a case of a 69-year-old male with multiple myeloma who accidentally took ixazomib daily for 3 days instead of the weekly regimen and thus coming into the hospital with an overdose. In this report, we focus on the adverse effects associated with ixazomib toxicity and how to manage the adverse reactions. Although there is no antidote available for ixazomib, supportive care is very essential in these patients.
多发性骨髓瘤是第二常见的血液系统恶性肿瘤。伊沙佐米是第一种在美国被批准用于治疗至少接受过一次前期治疗的多发性骨髓瘤的口服蛋白酶体抑制剂。口服化疗药物的出现使得那些不必来医院接受化疗输注的患者更容易接受治疗。然而，口服化疗存在许多障碍，其中之一是对用药说明的误解，这可能会产生有害影响。在本病例报告中，我们报告了一例 69 岁男性多发性骨髓瘤患者，他不小心每天服用伊沙佐米，连续服用了 3 天，而不是每周的方案，因此因药物过量而住院。在本报告中，我们重点介绍了与伊沙佐米毒性相关的不良反应以及如何管理这些不良反应。虽然目前没有针对伊沙佐米的解毒剂，但在这些患者中，支持性护理是非常重要的。
Zotero 插件